Rivanicline

Rivanicline

Clinical data
ATC code	none
Identifiers
IUPAC name (E)-N-Methyl-4-(3-pyridinyl)-3-butene-1-amine
CAS Number	15585-43-0 N
PubChem CID	5310967
IUPHAR/BPS	3994
ChemSpider	4470511 N
UNII	6H35LF645A
Chemical and physical data
Formula	C10H14N2
Molar mass	162.232
3D model (Jmol)	Interactive image
SMILES CNCC\C=C\C1=CN=CC=C1
InChI InChI=1S/C10H14N2/c1-11-7-3-2-5-10-6-4-8-12-9-10/h2,4-6,8-9,11H,3,7H2,1H3/b5-2+ N Key:JUOSGGQXEBBCJB-GORDUTHDSA-N N
NY (what is this?)

Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It has nootropic effects and was originally developed as a potential treatment for Alzheimer's disease, but a second action that was subsequently found was that it inhibits the production of Interleukin-8 and thus produces an antiinflammatory effect, and so it has also been developed as a potential treatment for ulcerative colitis. Rivanicline also has stimulant and analgesic actions which are thought to be mediated through stimulation of noradrenaline release, and so it could potentially also have other applications.